{"id":514359,"date":"2021-07-19T07:33:19","date_gmt":"2021-07-19T11:33:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/"},"modified":"2021-07-19T07:33:19","modified_gmt":"2021-07-19T11:33:19","slug":"bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/","title":{"rendered":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference"},"content":{"rendered":"
\n

NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time.<\/p>\n

To access the live webcast of BioXcel\u2019s presentation, please visit the \u201cEvents\u201d page within the News & Media section of the Company’s website at www.bioxceltherapeutics.com<\/a>. A replay of the webcast will be available on the Company\u2019s website for at least 30 days following the event.<\/p>\n

\n About BioXcel Therapeutics, Inc.<\/strong>\n <\/p>\n

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel\u2019s drug re-innovation approach leverages existing approved drugs and\/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel\u2019s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment na\u00efve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com<\/a>.<\/p>\n

Source: BioXcel Therapeutics, Inc.<\/p>\n

\n
\n
\n \n <\/div>\n

\n
Investor & Media:\r\n\r\nMary Coleman\r\nmcoleman@bioxceltherapeutics.com\r\n475-238-6837<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time. To access the live webcast of BioXcel\u2019s presentation, please visit the \u201cEvents\u201d page within the News & Media section of the Company’s website at www.bioxceltherapeutics.com. A replay of the webcast will be available on the Company\u2019s website for at least 30 days following the event. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and … <\/p>\n
Continue reading “BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-514359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time. To access the live webcast of BioXcel\u2019s presentation, please visit the \u201cEvents\u201d page within the News & Media section of the Company’s website at www.bioxceltherapeutics.com. A replay of the webcast will be available on the Company\u2019s website for at least 30 days following the event. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and … Continue reading "BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-19T11:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference\",\"datePublished\":\"2021-07-19T11:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/\"},\"wordCount\":237,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/\",\"name\":\"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=\",\"datePublished\":\"2021-07-19T11:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","og_description":"NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive Officer of BioXcel, will participate in the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 9:30 a.m. Eastern Time. To access the live webcast of BioXcel\u2019s presentation, please visit the \u201cEvents\u201d page within the News & Media section of the Company’s website at www.bioxceltherapeutics.com. A replay of the webcast will be available on the Company\u2019s website for at least 30 days following the event. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and … Continue reading \"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-19T11:33:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference","datePublished":"2021-07-19T11:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/"},"wordCount":237,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/","name":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=","datePublished":"2021-07-19T11:33:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MjA0MSM0MzAxNjE0IzIxOTI5NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-present-at-canaccord-genuity-41st-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=514359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/514359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=514359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=514359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=514359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}